### Indication
Necrotising fasciitis

### INN
Clindamycin

### Medicine type
Chemical agent

### Antibiotic groups
ACCESS

### List type
Core

### Formulations
- **Parenteral > General injections > IV:** 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate) (EML); 900 mg per 6 mL (as phosphate) (EML)
- **Oral > Liquid:** 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) (EMLc)
- **Oral > Solid:** 150 mg (as hydrochloride)

### EML status history
- First added in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

### Sex
- All

### Age
- Also recommended for children

### Therapeutic alternatives
- The recommendation is for this specific medicine

### Patent information
- Patents have expired in most jurisdictions
- Read more about patents.

### Wikipedia
- Clindamycin

### DrugBank
- Clindamycin

---

**Expert Committee recommendation**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:

- The addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.
- Replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc.
- The addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride)) on the EMLc.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc.

### EML recommendations: Necrotising fasciitis

**First choice**

**Second choice**
metronidazole
coprescribed with ceftriaxone

clindamycin
coprescribed with piperacillin + tazobactam

vancomycin